What happens to the embedded in-house dispute resolution process if the company turns away from the DEI (diversity, equity, and inclusion) policy for various reasons, including political ones? Or fear ...

On August 3, 2023, the U.S. Department of Health & Human Services (“HHS”), the Department of Labor, and the Department of Treasury (collectively, the “Departments”) temporarily suspended the federal ...

Alternative dispute resolution has many advantages over traditional litigation, including reduced costs, expedited timelines and streamlined processes. However, one of the oft-touted reasons parties ...

Hospital groups are asking Congress to consider dispute resolution methods, such as mediation and arbitration, as part of a legislative solution to stop surprise medical bills. In a May 28 letter to ...

On December 10, 2020, HRSA issued a final rule (the Final Rule) implementing the 340B Drug Pricing Program administrative dispute resolution (ADR) process–an overdue mandate from the Affordable Care ...

In a final rule on fees for disputed claims, Health and Human Services and other departments are finalizing an amount of $115 per party for disputes initiated on or after the effective date of this ...

The downsides to the No Surprises Act’s dispute resolution process The No Surprises Act was designed to remove the costs of out-of-network providers as a barrier to patient care, but its independent ...

The Centers for Medicare and Medicaid Services is extending independent dispute filing deadlines through at least mid-October after the Change Healthcare cyberattack threw the process into disarray.

The Biden administration has proposed a new rule refining several aspects of the healthcare services billing process in response to criticisms levied from all sides of the industry. Unveiled Friday ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Providers and drugmakers are once again at odds over the 340B drug discount program: this time, over a rule finalized by the Biden administration on Thursday making changes to its dispute resolution ...